Rep. Lisa C. McClain Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $207.75 on Thursday. The firm has a market cap of $500.53 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average price of $190.05 and a 200 day moving average price of $172.75.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently modified their holdings of the business. Vermillion & White Wealth Management Group LLC raised its holdings in Johnson & Johnson by 96.3% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 738 shares of the company’s stock worth $137,000 after buying an additional 362 shares during the period. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Johnson & Johnson during the third quarter worth $133,000. Connors Investor Services Inc. lifted its position in Johnson & Johnson by 3.0% in the 3rd quarter. Connors Investor Services Inc. now owns 3,451 shares of the company’s stock valued at $640,000 after acquiring an additional 100 shares in the last quarter. ARQ Wealth Advisors LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth $813,000. Finally, Manhattan West Asset Management LLC increased its holdings in Johnson & Johnson by 1.8% during the 3rd quarter. Manhattan West Asset Management LLC now owns 13,551 shares of the company’s stock worth $2,513,000 after purchasing an additional 234 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Scotiabank started coverage on Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target on the stock. HSBC upped their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Finally, Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.